- Citations, last 5 years
- 3 007
- Works, last 5 years
- 239
- h-index
- 86
- Scientists listed
- 26
- Grants since 2016
- 20
Grants received
2023–2025 · cooperative agreement · UG3
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
Roberto Ciccocioppo · United Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
Ravi Kumar Anchoori · United Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
Ravi Kumar Anchoori · United Therapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R41
Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma
Ravi Kumar Anchoori · United Therapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R41
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder
John R. Traynor · United Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R41
Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer
Ravi Kumar Anchoori · United Therapeutics (United States) · funded by National Institutes of Health
2022–2025 · contract · N01
DEVELOPMENT OF A NOVEL THERAPEUTIC FOR MELIOIDOSIS
M.R.K. Alley · United Therapeutics (United States) · funded by National Institutes of Health
2022–2024 · contract · N01
DEVELOPMENT OF A NOVEL THERAPEUTIC FOR MELIOIDOSIS
M.R.K. Alley · United Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · contract · N01
Development of a Novel Therapeutic for Melioidosis
M.R.K. Alley · United Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · research · R42
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder
John R. Traynor · United Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · contract · N01
Development of a Novel Therapeutic for Melioidosis
M.R.K. Alley · United Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · research · R42
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder
John R. Traynor · United Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R41
Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer
Ravi Kumar Anchoori · United Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases
Michael Jay · United Therapeutics (United States) · funded by National Institutes of Health
2019–2024 · research · R44
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases
Michael Jay · United Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R41
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases
Xiuling Lu · United Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Development of a Neonatal Abstinence Syndrome Therapy
Rick Hawkins · United Therapeutics (United States) · funded by National Institutes of Health
2018 · research · R44
Development of a Neonatal Abstinence Syndrome Therapy
Rick Hawkins · United Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Development of a Neonatal Abstinence Syndrome Therapy
Rick Hawkins · United Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R43
Development of Monoclonal Antibodies to the Alternative Complement Pathway-Specific Protein Activated Factor B (fBb)as Therapeutics for PNH
Tony Byun · United Therapeutics (United States) · funded by National Institutes of Health